ArticleTargeted oncology2023

Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma.

Hiroki Ishihara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.